阿尔茨海默病和帕金森病痴呆的脑代谢有所不同。
Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia.
作者信息
Griffith H Randall, den Hollander Jan A, Okonkwo Ozioma C, O'Brien Timothy, Watts Ray L, Marson Daniel C
机构信息
Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
出版信息
Alzheimers Dement. 2008 Nov;4(6):421-7. doi: 10.1016/j.jalz.2008.04.008.
Abstract
BACKGROUND
Few comparative studies exist of metabolic brain changes among neurodegenerative illnesses. We compared brain metabolic abnormalities in Alzheimer's disease (AD) and in Parkinson's disease with dementia (PDD) as measured by proton magnetic resonance spectroscopy (MRS).
METHODS
Twelve patients with idiopathic PDD, 22 patients with probable mild AD, and 61 healthy older controls underwent posterior cingulate MRS.
RESULTS
Patients with AD exhibited reduced N-acetyl aspartate (NAA)/creatine (Cr) (P < .05) and increased choline (Cho)/Cr (P < .05) and myo-inositol (mI)/Cr (P < .01) compared with controls. Patients with PDD exhibited reduced NAA/Cr (P < .05) and glutamate (Glu)/Cr (P < .01) compared with controls. There was reduced Glu/Cr in PDD compared with AD (P < .01).
CONCLUSIONS
Patients with AD and patients with PDD exhibited distinct brain metabolic MRS profiles. Findings suggest that comparison of brain MRS profiles across dementias provides useful direction for future study.
摘要
背景
关于神经退行性疾病中脑代谢变化的比较研究较少。我们通过质子磁共振波谱（MRS）比较了阿尔茨海默病（AD）和帕金森病痴呆（PDD）患者的脑代谢异常情况。
方法
12例特发性PDD患者、22例可能为轻度AD的患者以及61名健康老年对照者接受了后扣带回MRS检查。
结果
与对照组相比，AD患者的N-乙酰天门冬氨酸（NAA）/肌酸（Cr）降低（P <.05），胆碱（Cho）/Cr升高（P <.05），肌醇（mI）/Cr升高（P <.01）。与对照组相比，PDD患者的NAA/Cr降低（P <.05），谷氨酸（Glu）/Cr降低（P <.01）。与AD相比，PDD患者的Glu/Cr降低（P <.01）。
结论
AD患者和PDD患者表现出不同的脑代谢MRS特征。研究结果表明，比较不同痴呆症患者的脑MRS特征可为未来研究提供有用的方向。
相似文献
1
Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia.阿尔茨海默病和帕金森病痴呆的脑代谢有所不同。
Alzheimers Dement. 2008 Nov;4(6):421-7. doi: 10.1016/j.jalz.2008.04.008.
2
Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.在临床环境中，后扣带回皮质中的代谢物比率与帕金森病的认知衰退无关。
Parkinsonism Relat Disord. 2016 Jan;22:54-61. doi: 10.1016/j.parkreldis.2015.11.008. Epub 2015 Nov 12.
3
In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.阿尔茨海默病颞叶的体内质子磁共振波谱分析
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Dec;28(8):1313-22. doi: 10.1016/j.pnpbp.2004.08.013.
4
Early Alzheimer's disease neuropathology detected by proton MR spectroscopy.通过质子磁共振波谱检测早期阿尔茨海默病神经病理学
J Neurosci. 2014 Dec 3;34(49):16247-55. doi: 10.1523/JNEUROSCI.2027-14.2014.
5
Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia.无痴呆症的帕金森病患者会出现后扣带回代谢变化。
Neurosci Lett. 2004 Jan 16;354(3):177-80. doi: 10.1016/j.neulet.2003.09.076.
6
Brain glutamate levels are decreased in Alzheimer's disease: a magnetic resonance spectroscopy study.阿尔茨海默病患者大脑谷氨酸水平降低：一项磁共振波谱研究。
Am J Alzheimers Dis Other Demen. 2011 Sep;26(6):450-6. doi: 10.1177/1533317511421780. Epub 2011 Sep 15.
7
Decreased N-Acetyl Aspartate/Myo-Inositol Ratio in the Posterior Cingulate Cortex Shown by Magnetic Resonance Spectroscopy May Be One of the Risk Markers of Preclinical Alzheimer's Disease: A 7-Year Follow-Up Study.磁共振波谱显示后扣带回皮质 N-乙酰天门冬氨酸/肌醇比值降低可能是临床前阿尔茨海默病的风险标志物之一：一项 7 年随访研究。
J Alzheimers Dis. 2017;60(4):1411-1427. doi: 10.3233/JAD-170450.
8
Using proton magnetic resonance spectroscopy to identify mild cognitive impairment.利用质子磁共振波谱分析来识别轻度认知障碍。
Int Psychogeriatr. 2012 Jan;24(1):19-27. doi: 10.1017/S1041610211000962. Epub 2011 Jun 16.
9
Association of 1H-MR spectroscopy and cerebrospinal fluid biomarkers in Alzheimer's disease: diverging behavior at three different brain regions.阿尔茨海默病的 1H-MR 光谱和脑脊液生物标志物的相关性：三个不同脑区的不同行为。
J Alzheimers Dis. 2013;36(1):155-63. doi: 10.3233/JAD-120778.
10
Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease.采用3特斯拉磁共振波谱检测轻度认知障碍和阿尔茨海默病患者海马体和后扣带回区域的代谢变化。
Acta Radiol. 2009 Apr;50(3):312-9. doi: 10.1080/02841850802709219.
引用本文的文献
1
Role of in neurodegenerative diseases: current evidence and future directions.[具体内容]在神经退行性疾病中的作用：当前证据与未来方向。 （注：原文中“Role of ”后面缺少具体内容）
Front Pharmacol. 2025 Apr 9;16:1511011. doi: 10.3389/fphar.2025.1511011. eCollection 2025.
2
Early diagnostic value of neurotransmitter changes in vulnerable brain regions of patients with subjective cognitive decline detected using proton magnetic resonance spectroscopy.利用质子磁共振波谱检测主观认知衰退患者易损脑区神经递质变化的早期诊断价值。
Medicine (Baltimore). 2025 Feb 21;104(8):e41474. doi: 10.1097/MD.0000000000041474.
3
Therapeutic Potential of Experimental Stereotactic Hippocampal Cell Transplant in the Management of Alzheimer's Disease.实验性立体定向海马细胞移植在阿尔茨海默病治疗中的潜力
J Clin Med. 2025 Jan 29;14(3):891. doi: 10.3390/jcm14030891.
4
Neurometabolic topography and associations with cognition in Alzheimer's disease: A whole-brain high-resolution 3D MRSI study.阿尔茨海默病的神经代谢拓扑结构及其与认知的关联：全脑高分辨率 3D MRSI 研究。
Alzheimers Dement. 2024 Sep;20(9):6407-6422. doi: 10.1002/alz.14137. Epub 2024 Jul 29.
5
A comparative study of posterior cingulate metabolism in patients with mild cognitive impairment due to Parkinson's disease or Alzheimer's disease.帕金森病或阿尔茨海默病所致轻度认知障碍患者后扣带回代谢的对比研究。
Sci Rep. 2023 Aug 30;13(1):14241. doi: 10.1038/s41598-023-41569-5.
6
Chemical genetic activation of the cholinergic basal forebrain hippocampal circuit rescues memory loss in Alzheimer's disease.化学遗传学激活胆碱能基底前脑海马回路可挽救阿尔茨海默病的记忆丧失。
Alzheimers Res Ther. 2022 Apr 13;14(1):53. doi: 10.1186/s13195-022-00994-w.
7
Enhanced Medial Prefrontal Cortex and Hippocampal Activity Improves Memory Generalization in APP/PS1 Mice: A Multimodal Animal MRI Study.增强内侧前额叶皮质和海马体活动可改善APP/PS1小鼠的记忆泛化：一项多模态动物MRI研究
Front Cell Neurosci. 2022 Mar 21;16:848967. doi: 10.3389/fncel.2022.848967. eCollection 2022.
8
GuanXinNing Tablet Attenuates Alzheimer's Disease via Improving Gut Microbiota, Host Metabolites, and Neuronal Apoptosis in Rabbits.冠心宁片通过改善兔肠道菌群、宿主代谢产物及神经元凋亡减轻阿尔茨海默病。
Evid Based Complement Alternat Med. 2021 Oct 28;2021:9253281. doi: 10.1155/2021/9253281. eCollection 2021.
9
Magnetic resonance imaging and spectroscopy in late-onset GM2-gangliosidosis.磁共振成像和波谱在晚发型 GM2 神经节苷脂贮积症中的应用。
Mol Genet Metab. 2021 Aug;133(4):386-396. doi: 10.1016/j.ymgme.2021.06.008. Epub 2021 Jun 24.
10
Frontal lobe metabolic alterations characterizing Parkinson's disease cognitive impairment.额叶代谢改变是帕金森病认知障碍的特征。
Neurol Sci. 2021 Mar;42(3):1053-1064. doi: 10.1007/s10072-020-04626-9. Epub 2020 Jul 29.
本文引用的文献
1
Brain N-acetylaspartate is reduced in Parkinson disease with dementia.帕金森病伴痴呆患者脑内的N-乙酰天门冬氨酸减少。
Alzheimer Dis Assoc Disord. 2008 Jan-Mar;22(1):54-60. doi: 10.1097/WAD.0b013e3181611011.
2
Reduced brain glutamate in patients with Parkinson's disease.帕金森病患者大脑谷氨酸水平降低。
NMR Biomed. 2008 May;21(4):381-7. doi: 10.1002/nbm.1203.
3
Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease.阿尔茨海默病患者大脑中 scyllo-肌醇浓度升高。
NMR Biomed. 2007 Dec;20(8):709-16. doi: 10.1002/nbm.1132.
4
Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered.2005年斯坦利·法恩讲座：对散发性帕金森病相关包涵体病理学分期程序的重新审视。
Mov Disord. 2006 Dec;21(12):2042-51. doi: 10.1002/mds.21065.
5
Progression of white matter hyperintensities in Alzheimer disease, dementia with lewy bodies, and Parkinson disease dementia: a comparison with normal aging.
Am J Geriatr Psychiatry. 2006 Oct;14(10):842-9. doi: 10.1097/01.JGP.0000236596.56982.1c.
6
Treatment monitoring and response prediction with proton MR spectroscopy in AD.阿尔茨海默病中质子磁共振波谱的治疗监测与反应预测
Neurology. 2006 Aug 8;67(3):528-30. doi: 10.1212/01.wnl.0000228218.68451.31.
7
Cognitive decline correlates with neuropathological stage in Parkinson's disease.认知功能衰退与帕金森病的神经病理分期相关。
J Neurol Sci. 2006 Oct 25;248(1-2):255-8. doi: 10.1016/j.jns.2006.05.011. Epub 2006 Jun 30.
8
Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease.帕金森病中囊泡谷氨酸转运体VGLUT1和VGLUT2的表达改变
Neurobiol Aging. 2007 Apr;28(4):568-78. doi: 10.1016/j.neurobiolaging.2006.02.010. Epub 2006 Mar 24.
9
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.路易体痴呆的诊断与管理：DLB联盟的第三次报告
Neurology. 2005 Dec 27;65(12):1863-72. doi: 10.1212/01.wnl.0000187889.17253.b1. Epub 2005 Oct 19.
10
Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with lewy bodies and Alzheimer's disease.帕金森病合并痴呆个体患者的认知特征：与路易体痴呆和阿尔茨海默病的比较。
Mov Disord. 2006 Mar;21(3):337-42. doi: 10.1002/mds.20726.
Zotero 插件